Aprotiinin keuhkojen toimintaa suojaava vaikutus sydänleikkauksissa

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-004866-14-FI

Enrollment

Registered

2006-09-04

Start date

2006-10-09

Completion date

Unknown

Last updated

2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ohitusleikkaus MedDRA version: 8.1 Level: LLT Classification code 10011098 Term: Coronary bypass

Interventions

Trade Name: Trasylol Product Name: Trasylol Pharmaceutical Form: Intravenous infusion INN or Proposed INN: APROTININ CAS Number: 9004040 Pharmaceutical form of the placebo: Intravenous infusion Route

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: aprotiinin vaikutus keuhkojen suojaamisen sydänleikkauksen aikana;Secondary Objective: ;Primary end point(s):	—

Countries

Finland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026